cyrilzakka/clinical-trials huggingface dataset:
SeniorWorkingLife (Danish Title: SeniorArbejdsLiv)

Due to demographic changes across Europe there are strong political interests in maintaining the labour force by prolonging working life, i.e. increasing retirement age. The present study investigates push and stay mechanisms for labor market attachment among older (+50 yrs) workers or people who have recently retired.

Due to demographic changes across Europe there are strong political interests in maintaining the labour force by prolonging working life, i.e. increasing retirement age. The present study investigates push and stay mechanisms for labor market attachment among older workers or people who have recently retired. The study is a questionnaire survey, which is already funded. The ambition is to apply for further funding to do a cohort that is repeated every 2-3 years, as well as long-term register follow-up in Danish national registers about health and work.

The study has 4 target groups:

1. employed
2. unemployed
3. early retirement
4. disability pension

The questionnaire survey is sent to 30,000 Danish citizens and contains the following 14 areas:

1. Basic information (demographics, employment status etc.)
2. Broad overview of factors that may influence labor market attachment (health, working conditions, economic factors)
3. Role of the workplace
4. Age-discrimination
5. Economy
6. Specific questions about the possibility for 'early retirement' among employed and unemployed
7. Gradual retirement (e.g. possibility for reduced time or responsibility)
8. Competencies and continuing education/training of skills
9. Return-to-work
10. New technologies at the workplace
11. Job satisfaction and well-being
12. Working environment (physical, psychosocial etc.)
13. Lifestyle
14. Health and functional capacity

The study is supported by a grant from TrygFonden

Eligibility Criteria:
Inclusion Criteria:

Labor market status of:

* employed (employed at least 20/37 hours per week 1.quarter of 2018) OR
* unemployed (unemployed at least 20/37 hours per week 1.quarter of 2018) OR
* early retirement OR
* disability pension

Exclusion Criteria:

* those that do not fullfill the above inclusion criteria
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).


Eligibility Criteria:
Inclusion Criteria:

* - Subjects diagnosed with T2DM and treated with metformin equal to or above 1000 mg/day and SU (gliclazide, glipizide or glyburide/glibenclamide at maximum tolerated dose (at least half maximum approved dose) or glimepiride at maximum tolerated dose (at least 2 mg/day)), both at a stable dose for at least 90 days prior to screening. Stable is defined as unchanged medication and dose
* - HbA1c 7.0-10.0% (53- 86 mmol/mol) (both inclusive)
* - Body Mass Index (BMI) equal to or above 20 kg/m\^2
* - Subjects who have expressed their intention to fast (daytime, i.e. between sunrise and sunset) during Ramadan after receiving medical counselling regarding the risk of fasting

Exclusion Criteria:

* - Any contraindication for successful and sustained fasting from a medical perspective at the discretion of the investigator (such as acute illness, severe hypoglycaemia within 90 days prior to screening, a history of recurrent hypoglycaemia, hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening, hyperosmolar hyperglycaemic coma within 90 days prior to screening, subjects performing intense physical labour)
* - Any chronic disorder or severe disease which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol
* - History of chronic pancreatitis or idiopathic acute pancreatitis
* - Screening calcitonin value equal to or above 50 ng/L
* - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
* - Impaired liver function, defined as alanine aminotransferase (ALAT) equal to or above 2.5 times upper normal limit (UNL)
* - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m\^2 per Modification of Diet in Renal Disease (MDRD) formula)
* - Any episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack (TIA) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening
* - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
IMPact of AerobiC Exercise in Addition to Nutritional Treatment on Quality of Life After Pancreatectomy

The goal of this interventional study is to assess the impact of a 6-month unsupervised aerobic exercise program on the quality of life of patients undergoing partial or total pancreatectomy. The main question it aims to answer is:

Does an aerobic exercise program improve physical functioning and overall quality of life in post-pancreatectomy patients?

Eligible participants will be assigned to either an exercise group or a control group. Quality of life will be evaluated using standardized scoring scales, with a focus on physical functioning. Secondary outcomes include changes in metabolic parameters (glycemia, HbA1c, lipid profile), BMI, and overall survival.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Male or female patients who have undergone partial or total pancreatectomy
* Age ≥18 and ≤80 years
* Ability to understand and complete questionnaires and willingness to participate in periodic assessments
* No symptoms suggestive of cardiovascular issues (e.g., angina, dyspnea, palpitations, syncope)
* No evidence of ischemic heart disease, cardiomyopathy, valvular heart disease, myocarditis, autoimmune diseases, infections, or fractures that would contraindicate moderate-intensity aerobic activity

Exclusion Criteria:

* Age \>80 or \<18 years
* Cardiovascular, musculoskeletal, rheumatologic, or neurocognitive disorders contraindicating aerobic exercise
* 10-year cardiovascular risk \>20% without cardiological/sports medicine evaluation
* Diagnosis of unresectable tumor
* Presence of metastases
* Pregnancy or breastfeeding
* Ongoing chemotherapy and/or radiotherapy
* BMI ≥30
* BMI ≤18.5
Edge-to-edge Mitral Valve Repair in ATTR-CM

No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient population was specifically excluded from previous large TEER trials. From a pathophysiological perspective, effective treatment of significant regurgitant volume and consecutive improvement of forward volume appears highly desirable in a condition with intrinsically low output. However, whether this translates into improved functional capacity, better quality of life, and better clinical outcomes compared to conservative heart failure management alone remains to be investigated.

It is the aim of this trial to investigate the effectiveness of TEER therapy in patients with proven ATTR-CM and concomitant significant MR as compared to medical therapy alone. Effectiveness will be tested via hard clinical outcomes, biomarkers, functional capacity, and quality of life.

Eligibility Criteria:
Inclusion criteria (all must be present)

* Proven ATTR-CM
* Significant symptomatic MR (3+ or 4+ by independent echocardiographic core laboratory assessment)
* Subject has been adequately treated per applicable standards, including for coronary artery disease and heart failure (e.g., diuretics)
* New York Heart Association (NYHA) functional class II, III, or ambulatory IV
* Local heart team has determined that mitral valve surgery will not be offered as a treatment option, even if the subject is randomized to the control group
* Left ventricular ejection fraction ≥20%
* Anatomical feasibility for TEER as per discretion of the implanting investigator
* Age 18 years or older
* Subject or guardian agrees to all provisions of the protocol, including the possibility of randomization to the Control group and returning for all required post-procedure follow-up visits, and has provided written informed consent

Exclusion criteria (all must be absent)

* AL-associated cardiomyopathy
* Aortic or tricuspid valve disease requiring surgery or transcatheter intervention
* Severe right ventricular dysfunction
* Hemodynamic instability requiring inotropic support or mechanical heart assistance
* Leaflet anatomy which may preclude TEER, proper device positioning on the leaflets or sufficient reduction in mitral regurgitation by TEER
* Life expectancy \<12 months due to non-cardiac conditions
* Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
* Echocardiographic evidence of intracardiac mass, thrombus or vegetation
* Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)
* Active infections requiring current antibiotic therapy
* Transesophageal echocardiography (TEE) is contraindicated or high risk
* Pregnant or planning pregnancy within next 12 months
* Currently participating in another investigational device study that has not reached its primary endpoint
7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy

This clinical trial study aims to detect the imaging characteristics of patients with hepatic encephalopathy (HE) using 7-Tesla (7T) magnetic resonance imaging (MRI).

In this study, we analyzed the imaging characteristics of HE. First, with the advantages of 7TMRI, we analyzed the differences in imaging characteristics between HE patients and the healthy, including brain functional imaging and structural imaging. Second, we analyzed the differences in imaging characteristics between different subgroups of HE patients. Finally, we analyzed the correlation between the prognostic results of HE patients after follow-up and the imaging characteristics.

Eligibility Criteria:
Inclusion Criteria:

* Patients with clinical suspected or diagnosed hepatic encephalopathy according to relevant guidelines.The patient's education level is above primary school level.
* Regular follow-up.

Exclusion Criteria:

* Contraindications to MRI.
* Patients with cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease.
A Retrospective, Observational Registry of Participants With Avian Influenza Infection

This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1. Data are collected through retrospective abstraction, from detailed case reports that may be published and available in the public domain, or as incident cases received directly from the treating physician or other medical personnel.


Eligibility Criteria:
Inclusion Criteria:

* Participants who develop influenza-like symptoms and who are considered to be epidemiologically linked by time, place, and exposure to a probable or confirmed avian influenza or human case of H5N1 infection are eligible for inclusion in the Registry. Cases with atypical symptom presentation (e.g., non-respiratory) are also included, in keeping with evolving knowledge about the clinical presentation of avian influenza.
* Participants with documented positive serological test who either remain asymptomatic or experience mild illness only
* Participants with laboratory confirmation of infection with influenza A (H5N1) who survive long enough to present for medical care

Exclusion Criteria:

- There are no exclusion criteria in this study
Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)

seroPREvalence vis-à-vis SARS-CoV2 and correlation with clinical forms of COVID-19 in patients followed in Pulmonology in the cluster area of the Grand-Est region.


Eligibility Criteria:
Inclusion Criteria:

* Man or woman from 18 years old and without upper age limit
* Patient followed in pulmonology at Strasbourg University Hospital
* Patient presenting at least one of the following pathologies:

  1. severe persistent asthma (200 patients)
  2. chest cancer that is active or has received treatment within a period of less than one year (300 patients)
  3. history of lung transplantation performed before the start of the epidemic (02/29/2020) (300 patients)
  4. idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis (70 patients)
  5. pulmonary arterial hypertension (PAH) (group 1 of the international classification) any cause or chronic thromboembolic PAH (group 4): (60 patients)
  6. Severe COPD in the respiratory failure stage (150 patients)
* Subject affiliated to a social health insurance protection scheme
* Subject able to understand the objectives of the research
* Subject having signed an informed consent

Exclusion Criteria:

* Inability to provide informed information about the subject (subject in an emergency situation, difficulty in understanding the subject, etc.)
* Subject under safeguard of justice
* Subject under guardianship or guardianship
The Effect of Intraoperative Body Temperature on Postoperative Nausea and Vomiting in Pediatric Patients

The aim of our study was to investigate the effects of changes in body temperature in the perioperative period on postoperative nausea and vomiting.

Undesirable hypothermia is that the perioperative body temperature is below 36 ° C. Perioperative heat loss is higher in pediatric patients than in adult patients. One of the most common side effects of general anesthesia is nausea and vomiting. The aim of our study was to investigate the effects of changes in body temperature in the perioperative period on postoperative nausea and vomiting.We planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery. In all patients, heating blanket was placed on the operation table and standard heat was used. After the placement of the LMA, a nasopharyngeal heat probe was placed for central body temperature measurement and monitored throughout the operation. Mean arterial pressure, heart rate and body temperature were recorded. Demographic data, type of operation, duration of operation and intraoperative fentanyl requirement of all cases were recorded. Analgesic and antiemetic requirements, presence of nausea and vomiting (according to numerical sequence scale) were recorded in the recovery room at 6, 12 and 24 hours postoperatively

Eligibility Criteria:
Inclusion Criteria:

* ASA1 group
* Aged 6 months to 7 years
* lower abdominal and urological surgery

Exclusion Criteria:

* Upper abdominal surgery
* ASA 2-3 group
* postoperative nausea and vomiting history
H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women

Pregnant women are at particular risk during the imminent H1N1v influenza pandemic. The new H1N1v virus requires urgent political and medical decisions on vaccination strategies in order to minimize severe disease and death from this pandemic. However, there is a lack of evidence to build such decisions upon. A vaccine will be provided in the fourth quarter of 2009, but there is little knowledge on the immunogenicity. Particularly its clinical effectiveness and duration of immunity in pregnant women and their newborn infants is unknown. Therefore, it will be important to study the optimal vaccination regimens with respect to dosing and use of adjuvant to decide future health policies on vaccination of pregnant women. We have a unique possibility to study these aspects of H1N1v infection in pregnant women in our ongoing unselected, prospective, birth-cohort study recruiting 800 pregnant mothers between Q1- 2009 and Q4-2010. Pregnant women from East-Denmark are being enrolled during the 2nd trimester and their infant will undergo a close clinical follow-up. The H1N1v pandemic is expected to reach Denmark Q4-2009. The timing of this enrollment and the imminent pandemic allows for an "experiment of nature" whereby the first half of the mothers completes pregnancy before the H1N1v pandemic. The other half of this cohort will be pregnant while H1N1v is prevalent in the community and will require H1N1v vaccination. The aim of this randomized, controlled, trial is to compare and evaluate the dose-related immune protection conferred by vaccine and adjuvant (Novartis vaccine Focetria) in pregnant women and non-pregnant women. In addition the protocol will assess the passive immunity conferred to the newborn from these vaccine regimes. The study will provide evidence-based guidance for health policies on vaccination for the population of pregnant women during future H1N1v pandemics.


Eligibility Criteria:
Inclusion Criteria:

* Healthy pregnant and non pregnant women living in Eastern Denmark
* Fluent in Danish

Exclusion Criteria:

* Heart disease, endocrine disease, tuberculosis and sarcoidosis.
* History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, to any excipients, and to eggs (including ovalbumin), and chicken proteins.
The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients

Describe strengths and limitations of FDG PET/CT for staging. Evaluate the utility of PET/CT in assessment of therapy response and restaging

Lung cancer is one of the most common cancers and it represents the main cause of cancer mortality worldwide.

It is histopathological classified into main groups: Small cell lung cancer (15%) and Non-small cell lung cancer (85%). NSCLCs are generally subcategorized into adenocarcinoma, squamous cell carcinoma (SqCC), and large cell carcinoma. Positron emission tomography (PET) is now an important cancer imaging tool, both for diagnosis and staging, as well as offering prognostic information based on response.

PET sets the gold standard in the evaluation of an indeterminate solitary pulmonary nodule or mass, where PET has proven to be significantly more accurate than computed tomography (CT).

For NSCLC chest CT is the standard imaging modality for assessing primary tumor size and identifying its margins. PET-CT may be helpful in assessing a nodule located in same lobe. It can also provide information on parietal or mediastinal involvement. PET is useful for differentiating tumor tissue from atelectasis, which may be helpful if radiotherapy is planned to determine the target volume .

In the evaluation of metastatic spread to loco-regional lymph nodes, PET is significantly more accurate than CT, so that invasive surgical staging may be omitted in many patients with negative mediastinal PET images.

In patients with positive mediastinal PET images, invasive surgical staging remains mandatory because of the possibility of false-positive findings due to inflammatory nodes or granulomatous disorders.

Forty percent of patients with NSCLC have distant metastases at presentation, most commonly in the adrenal glands, bones, liver, or brain .

In the search for metastatic spread, PET is a useful adjunct to conventional imaging. This may be due to the finding of unexpected metastatic lesions or due to exclusion of malignancy in lesions that are equivocal on standard imaging. However, at this time, PET does not replace conventional imaging.

The diagnostic accuracy of initial pre-therapy PET-CT results in improved staging, and thus is of high prognostic value.

Many studies conducted the value of using semi-quantitative measures as metabolic tumor volume (MTV) and Total lesion glycolysis (TLG) in predicting prognosis and survival rather than the traditional method of measuring Standard uptake value (SUV).

Several studies have demonstrated that PET imaging proves useful for assessing the response to chemo therapy or targeted therapy in patients with metastatic NSCLC.

Eligibility Criteria:
Inclusion Criteria:

* Patients with pathologically proven lung cancer and referred to nuclear medicine unit to perform PET/CT for staging and patient referred for assessment of response of therapy and re staging.

Exclusion Criteria:

* Pregnant women.
* Patients unable to sleep in a fixed position for 20 minutes.
* Severely ill patients who aren't capable of complying with study procedures or comatose patients.
* Patients with known second primary
Local Methotrexate Injections for the Treatment of Nail Psoriasis

The investigators hope to learn the efficacy of methotrexate injections for treatment of nail psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Subject must be at least 18 years of age
* Subject must have nail psoriasis that is clinically diagnosed in at least 3 fingernails

Exclusion Criteria:

* Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study. This is including, but not limited to: immunodeficiency, onychomycosis, any other nail condition other than psoriasis, allergy to methotrexate, triamcinolone acetonide, local anesthetic, normal saline, or any other material used for procedures
* Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of study, and/or oral corticosteroids or IV methotrexate for \>1 month within the 6 months of study (exception inhaled steroids);
* Subjects who use substances (medications, supplements, ect) known to significantly interact with drugs used as intervention in the study
* Subject who is pregnant, breastfeeding, or planning to get pregnant
* Subject known to have received treatment with investigational drugs or devices within 30 days prior to enrollment into this study
* Subject who is on systemic treatment for psoriasis
* Subject with baseline abnormalities in liver function tests or complete blood count
* Subjects with diagnosis of renal insufficiency or impairment
* Subject who is unwilling to abstain from any cosmetic nail treatments outside those provided by the study clinic, beyond basic nail trimming (i.e. no spa nail treatments, no nail polish use, no other topical prescription nail medication)
* Subject who is unwilling to abstain from any medical nail treatments on their nails other than the study intervention (i.e. topical steroids, antifungal creams) for the duration of the study intervention and for duration of the washout period (if applicable)
* Subject who is part of the staff personnel directly involved with this study or a family member of the investigational study staff